RCC Market Snapshot: In A Crowded Field, What's Next?
Executive Summary
Just five years ago, the treatment options for patients with advanced kidney cancer were limited, but today, the market for renal cell carcinoma drugs is one of the most crowded in the oncology field, with six targeted agents on the market and more on the way
You may also be interested in...
Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer
Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.
Market Snapshot: Taking Constipation Seriously – Linaclotide Success Raises Hopes For Market Resurgence
The constipation and irritable bowel syndrome markets have sucked up some prescription drug contenders like quicksand. But the Phase III success of Ironwood Pharmaceuticals' linaclotide is renewing hope that an underserved and arguably under-appreciated market could blossom, despite regulatory and commercial challenges that have hindered candidates in the past.